Babesiosis is a tick-borne hemoparasitic disease affecting horses worldwide. To investigate mechanisms of immunity to this parasite, the antibody response of infected horses to Babesia equi merozoite proteins was evaluated. Immunoprecipitation ofB. equi merozoite antigens with sera from infected horses revealed 11 major proteins of 210, 144, 108, 88, 70, 56, 44, 36, 34, 28, and 25 
Equine babesiosis, caused by Babesia equi or Babesia caballi, is a tick-borne hemoprotozoan disease of horses (10, 16, 26) . Clinical disease is characterized by fever, anemia, and icterus (10, 26) , most likely arising from hemolysis caused by merozoites, the intraerythrocytic stage of equine Babesia infection. Mortality rate is high during initial infection of horses introduced into enzootic regions (26) , and horses which survive initial infection are protected from clinical disease upon subsequent challenge (26) . It is hypothesized that this immunity acquired by horses in enzootic areas is the result of persistent infection (26) .
Merozoite surface proteins are important in the pathogenesis of hemoprotozoan diseases because of their role in parasite recognition of, attachment to, and penetration of host erythrocytes (12) . Antigens recognized by antibody from hosts demonstrating immunity to clinical disease during Plasmodium spp., B. rhodhaini, B. bovis, and B. bigemina infection include surface proteins of merozoites (3, 8, 11, 19, 30) , the only blood stage of the parasite that is extracellular and directly accessible to serum antibody (11) . It was demonstrated that cattle immune to infection with B. bovis had high-titered antibody preferentially directed against four immunodominant merozoite surface proteins (8) . Invasion of erythrocytes by merozoites of Plasmodium knowlesi was inhibited by immune sera (3) , and inhibition of P. falciparum merozoite invasion of erythrocytes in vitro required high concentrations of specific antibodies (25) . These observations suggest that antibody to merozoite surface proteins may block erythrocyte invasion in vivo and that these proteins should be tested as potential immunogens.
Detection of antibodies has been the method of choice for * Corresponding author.
diagnosis of infection with equine Babesia spp. (4-6, 17, 27-29) ; however, the specificity or role of antibodies in the acquired protective immunity against clinical disease following equine Babesia infection has not been determined. To investigate mechanisms of the acquired protective immunity, the antibody response to B. equi merozoite proteins expressed during parasitemia was evaluated. The results presented in this report identify B. equi merozoite proteins recognized by sera from infected horses. Also Production of MAb. Eight-week-old BALB/c mice were immunized subcutaneously with 107 viable merozoites in 0.1 ml of phosphate-buffered saline (PBS) emulsified in an equal volume of Freund's complete adjuvant. Merozoites for MAb production were prepared from stabilates containing a 49% parasitemia. The stabilates were diluted with 2 volumes of PBS and centrifuged at 2,500 x g for 5 min. Pellets were lysed for 30 s with an equal volume of distilled water, diluted with 3 ml of PBS, vortexed gently, and centrifuged at 400 x g for 5 min. The supernatant was centrifuged at 2,500 x g to pellet the merozoites. Two additional immunizations consisting of the same number of parasites in incomplete Freund's adjuvant were given subcutaneously at 10-day intervals. The mice were then immunized intravenously with 107 viable merozoites in 0.1 ml of PBS 72 h prior to fusion. Cell fusions and cloning by limiting dilution were performed as described previously (23) . Heavy-chain isotypes were b Dilution of serum reducing OD values to less than 3 standard deviations below the mean for control horses (<0.73) in CI ELISA with MAb 36/133.97. OD for control horses at a 1/2 dilution = 0.97 + 0.08 (n = 68). Controls included preinoculation sera of H5 and SN76N8401 (control serum from the National Veterinary Services Laboratory, Ames, Iowa).
identified by enzyme-linked immunosorbent assay (ELISA), and concentrations of antibodies were determined by immunodiffusion (14) . Supernatants from the initial fusion and from limiting-dilution clones were screened by IFA with acetone-fixed B. equi organisms.
Immune sera from horses experimentally and naturally infected with B. equi. Serum was obtained from an adult horse (H5) infected intravenously twice at a 2-month interval with a Florida isolate of B. equi. After 50 ml of serum was obtained, the initial inoculation of H5 was with 30 ml of a first-passage stabilate of a Florida isolate of B. equi. This stabilate in 10% dimethyl sulfoxide contained 5.6 x 106 viable merozoites per ml. The second inoculation was with a 2.0-ml stabilate containing a 49% parasitemia prepared as described for B. equi isolates. Equine sera that tested positive for antibodies to B. equi by the complement fixation test (9) were obtained from the National Veterinary Services Laboratory, U.S. Department of Agriculture, Ames, Iowa. These sera were obtained from horses in 19 countries (Table 1) .
Immunoprecipitation and SDS-PAGE. Immunoprecipitation of radiolabeled antigen was performed as previously described (19) a 5% stacking gel (31) . SDS-polyacrylamide gels were processed for autoradiography as described previously (2) . 14C-labeled standards used for molecular weight comparisons (Amersham, Arlington Heights, Ill.) consisted of myosin (200,000), phosphorylase b (92,500), bovine serum albumin (69,000), ovalbumin (46,000), carbonic anhydrase (30,000), and lysozyme (14,300).
Western immunoblotting. Western blotting was performed on a miniblotter 25 (Immunetics, Cambridge, Mass.) by modification of published techniques (32) . Merozoite antigen was prepared from stabilates containing a 49% parasitemia as described for MAb production. Control erythrocyte antigen was prepared identically to merozoite antigen and was obtained from stabilates prepared from an uninfected horse. Pelleted merozoites were added to equal volumes of SDS-PAGE sample buffer and boiled for 10 min. Merozoite proteins separated in SDS-PAGE (as described above) were electrophoretically transferred overnight to nitrocellulose filters in 25 mM Tris-190 mM glycine buffer containing 20% (vol/vol) methanol. Filters were blocked for 2 h in 0.17 M NaCl-0.01 M Tris-0.1 mM phenylmethylsulfonyl fluoride-1.0% (wt/vol) bovine hemoglobin (buffer A). Serum (50 ,ul) or MAb (10 ,ug) was diluted in buffer A with the addition of 0.1% (wt/vol) SDS-0.1% (vol/vol) Triton X-100-1.0 mM EDTA (buffer B). Bound antibodies were detected by incubation for 1 h each in second antibody (rabbit anti-horse or rabbit anti-murine immunoglobulin) and '25I-protein A in buffer B. Filters were washed three times in buffer B after incubation with equine serum or MAb, second antibody, and 125I-protein A, followed by three washes in buffer B without hemoglobin before drying and autoradiography. '4C-labeled molecular weight standards were the same as for SDS-PAGE (see above).
IFA. (i) Fixed B. equi. IFA of acetone-fixed B. equi was performed as described previously (20) . Bound murine or equine antibodies were detected with fluorescein isothiocyanate-conjugated rabbit anti-mouse immunoglobulin or goat anti-horse immunoglobulin.
(ii) Live B. equi. Merozoites for live IFA were prepared from stabilates containing a 49% parasitemia as described for MAb production. Live IFA was performed by minor modification of previously described methodology (7 Addition of avidin-conjugated alkaline phosphatase (Vector Laboratories) in buffer B was followed by a 30-min incubation. Wells were washed three times with buffer B, and 100 ,u of a 1.0-g/p.l solution of p-nitrophenyl phosphate in 100 mM NaHCO3 (pH 9.5) with 10 (Fig. 3B , arrowheads) which comigrated with proteins immunoprecipitated by serum from horse H5 at 10-3 to 10-' dilutions ( 3A). In vitro translation products derived from rabbit reticulocyte lysate are not glycosylated (33) . Therefore, immunoprecipitation of these products by MAb 36/133.97 indicates that the binding site recognized by this antibody is a protein epitope. Immunoprecipitation of in vitro-translated B. equi mRNA with sera from four naturally infected horses provided similar results (data not shown).
In Western blot analysis, MAb 36/133.97 did not react with antigen from uninfected erythrocytes (data not shown); however, it recognized proteins of 44, 36, 34, and 28 kDa prepared from stabilates of infected erythrocytes (Fig. 4,  arrowheads) . Evaluation of diluted horse sera demonstrated reactivity with a 28-kDa protein at a dilution of (Fig. 4) In related hemoprotozoan diseases, such as malaria and bovine babesiosis, a prominent feature of the host reaction to infection is a preferential antibody response to protein antigens of merozoites (1, 8) . Observations indicate that the immune response to immunodominant merozoite surface proteins is involved in protection against clinical disease in bovine babesiosis and malaria (8, 25) and that antibody to merozoite surface proteins may block merozoite invasion of erythrocytes in vivo (3) . Similar to other hosts infected with hemoparasites (1, 3, 8, 19, 30) , horses respond to B. equi infection by producing antibodies to merozoite proteins.
Vaccination is currently not available for B. equi. Our strategy for development of immunoprophylaxis is to identify and characterize surface antigens of the merozoite, because this stage is infective for erythrocytes and is accessible to the host immune system (11, 12) . The data of this report identify means for the further characterization and isolation of a surface merozoite protein of B. equi which contains a geographically conserved protein epitope. The 
